Nurosene Health (MEND-CSE)

AI technology that lets drug companies screen out participants for trials. Pinpoints who they should include and who they shouldn't, leading to more success of trials. Doing an excellent job. Waiting for a bigger contract from a bigger company. Hasn't performed that well, but worst is behind them.

It has AI technology which helps drug companies through the trial process. Its technology targets and enrolls new patients with the right type of background and makeup.

AI software to help drug companies to purpose different compounds to tell what's effective and what's not. Part of the small cap selloff. Continues to reach significant milestones and sign contracts. Revenue and cashflow should improve over next year. A takeout possibility.

Stock's pulled back due to tax-loss selling. Business itself is interesting with the move to health and wellness. AI acquisition should let them work with big drug companies to study effects on mental health. This year should be strong as they roll out products and gain market share.

They are in the healthcare technology sector. Specializing in brain health. They have an app and technology tool that develops a baseline for everyone. Then they have actionable items to monitor and improve brain health. They have a direct to consumer subscription service.

They just IPO'd that he participated in. It's on the CSE, so he didn't make it a top pick today. Brain health is moving to the forefront. They combine tech and natural ingredients to promote brain health, like apps to keep the mind sharp. Michael Phelps is on the board among other notables. He's watching it. The company has room to grow.